2026-10-10T19:01:45Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34012497 2026-09-28T08:57:33Z category_319 portal_316 item_type_3 month_year_09_2026

Table 2_Pilot clinical study of Taxifolin Aqua effect in patients with amnestic mild cognitive impairment.docx Elena V. Ponomareva (25121274) Natalya D. Selezneva (25121277) Irina S. Boksha (25121280) Olga K. Savushkina (25121283) Tatyana A. Prokhorova (25121286) Elena B. Tereshkina (25121289) Svetlana A. Zozulya (25121292) Svetlana I. Gavrilova (25121295) Igor V. Kolykhalov (25121298) Psychiatry (incl. Psychotherapy) antio×idant biochemical blood analysis mild cognitive impairment Taxifolin treatment response <p>Taxifolin (dihydroquercetin), a potent antioxidant flavonoid, shows promise for neurodegenerative conditions. Our pilot study aimed at evaluation the efficacy and safety of Taxifolin in patients with amnestic mild cognitive impairment (aMCI) and monitored a set of blood measures. Twenty-three patients (18 female; aged 53-87) received dihydroquercetin oral solution for 8 weeks with a 4-week follow-up period in an open-label study design. Thirteen patients with aMCI were monitored as controls. Outcomes were assessed using cognitive status (MMSE, MoCA, FCSRT-IR), neuropsychiatric symptoms’ (NPI-Q, HDRS), and rater's impression (CGI) scales, along with blood measures monitoring (glutathione reductase (GR), glutamate dehydrogenase (GDH), and superoxide dismutase (SOD); plasma neutrophil elastase (NE), alpha-1-proteinase inhibitor (alpha-1PI)). Responder classification using composite Z-score changes was based on all clinical scales. Results: Eleven patients were classified as responders, showing significant MMSE and MoCA improvement (mean +2.73 points, p=0.001) sustained through 4-week follow-up. Non-responders and control group showed slight cognitive decline. Composite Z-score changes at the 4-week follow-up revealed differences between responders/non-responders (ANOVA F(2,20)=17.38, p=0.001); biomarker analysis revealed difference in NE/alpha-1PI ratio (p=0.034), SOD (p=0.023), and GR dynamics (p=0.022), which correlated negatively with clinical response (R=-0.547, p=0.007), and baseline GDH (p=0.049). Conclusion: Taxifolin treatment resulted in significant cognitive benefits in ~half of aMCI patients, with effects sustained for one month post-treatment. Biomarker changes reveal possible mechanisms involving oxidative stress modulation and inflammatory pathways. These findings support further controlled trials of Taxifolin in populations at risk of Alzheimer's disease.</p> 2026-09-28T08:57:33Z Dataset Dataset 10.3389/fpsyt.2026.1814042.s002 https://figshare.com/articles/dataset/Table_2_Pilot_clinical_study_of_Taxifolin_Aqua_effect_in_patients_with_amnestic_mild_cognitive_impairment_docx/34012497 CC BY 4.0